Evaluation of the Efficacy of an Antioxidant Dressing in Chronic Wound Healing (REOX)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Jaén, Spain, 23071
- Universidad de Jaén
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients over 18 years of age.
- Patients with leg ulcers (venous, ischemic, traumatic or diabetic foot ulcer).
- Patients with dehisced surgical wounds healing by second intention.
- Patients with pressure ulcers.
- Wound area between 1 and 250 cm2.
Exclusion Criteria:
- Systemic inflammatory disease or oncological disease.
- Wounds with clinical signs of infection.
- Terminal situation (life expectancy less than 6 months).
- Ulcers from other etiologies: tumours, infectious.
- Wounds treated with negative pressure therapy.
- Pregnancy.
- History of sensitivity or allergy to any of the components of the study dressing.
In addition, criteria for withdrawal from the study will be considered:
- Worsening of the wound according to the clinical judgment of the professional (appearance of clinical signs of infection or others).
- Appearance of allergies or hypersensitivity to the dressing.
- Death.
- Hospital admission that interrupts or complicates the continuity of care in the Nursing Consultation.
- Transfer to another Health District where there can be no continuity of care with the active dressing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Antioxidant dressing (active product)
|
Antioxidant dressing (active product), covered with secondary dressing. Compression bandage if necessary. Device: Reoxcare® |
|
Active Comparator: Usual care dressing (standard clinical practice)
|
Usual care dressing; moist environment dressing chosen from the study centres' formulary (hydrocolloid, alginate, polyurethane foam dressings, silver dressings).
Compression bandage if necessary
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the score of the RESVECH 2.0 scale for chronic wound healing monitoring
Time Frame: At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
The RESVECH 2.0 is a scale for monitoring the cicatrization of the wound.
It has 6 items: size of the lesion, depth/tissue concerned, edges, type of tissue in the wound bed, exudate, infection/inflammation.
The scale is scored numerically and can score ranging from 0 to 35 points, wound healed and the worst possible lesion respectively
|
At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
|
Wound size reduction
Time Frame: At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
Difference in wound area between first and last dressing
|
At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time required to achieve 50% reduction in wound size
Time Frame: Change from baseline to 8 weeks of follow up
|
Change from baseline to 8 weeks of follow up
|
|
|
Time to removal of non-viable tissue from wound bed
Time Frame: At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
|
|
Number of completely healed wounds
Time Frame: At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
|
|
Pain level
Time Frame: At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
The visual analogue scale (VAS) is commonly used as the outcome measure for patient´s pain.
It is usually presented as a 100-mm horizontal line on which pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable."
|
At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
|
Area of wound with bacterial load
Time Frame: At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
clinical signs of infection and/or measurement of surfaces with bacteria
|
At baseline, after 2 week, after 4 week, after 6 week and after 8 week
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Castro B, Bastida FD, Segovia T, Lopez Casanova P, Soldevilla JJ, Verdu-Soriano J. The use of an antioxidant dressing on hard-to-heal wounds: a multicentre, prospective case series. J Wound Care. 2017 Dec 2;26(12):742-750. doi: 10.12968/jowc.2017.26.12.742.
- Castro B, Palomares T, Azcoitia I, Bastida F, del Olmo M, Soldevilla JJ, Alonso-Varona A. Development and preclinical evaluation of a new galactomannan-based dressing with antioxidant properties for wound healing. Histol Histopathol. 2015 Dec;30(12):1499-512. doi: 10.14670/HH-11-646. Epub 2015 Jul 3.
- Comino-Sanz IM, Lopez-Franco MD, Castro B, Pancorbo-Hidalgo PL. Antioxidant dressing therapy versus standard wound care in chronic wounds (the REOX study): study protocol for a randomized controlled trial. Trials. 2020 Jun 8;21(1):505. doi: 10.1186/s13063-020-04445-5.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TD-REOX-2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.